Comprehensive Treatment and Monthly 2 Year Follow-Up in Children With ADHD: Randomized Controlled Prospective Study.

J Atten DisordSep 5, 2026 (epub)
Clinical ResearchPsychiatryPediatrics

Lily Hechtman, Natalie Grizenko, Ridha Joober et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the efficacy of regular monthly follow-up versus as-needed follow-up in maintaining treatment gains in 186 children aged 6 to 13 with ADHD. After an initial 3-month comprehensive treatment, both groups showed significant improvements, but the community group exhibited worse Hyperactive/Impulsive ratings over the 2-year follow-up period.

Key findings

  • Both groups showed significant improvements in all domains after 3 months of treatment.
  • Hyperactive/Impulsive ratings were worse in the community follow-up group during the follow-up period.
  • Treatment gains were maintained for 2 years in both groups.

Why it matters

Understanding the impact of follow-up frequency on treatment outcomes in children with ADHD is crucial for optimizing care strategies. This study highlights the potential benefits of structured follow-up in maintaining treatment gains.

Source

PubMed · PMID 42698352

Published in J Atten Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.